TAVO-412 is under clinical development by Tavotek Biotherapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAVO-412’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAVO-412 overview
TAVO-412 is under development for the treatment of advanced and metastatic solid tumors, gastroesophageal junction cancer (including lower esophageal adenocarcinoma), non-small cell lung cancer, triple-negative breast cancer, gastric cancer, pancreatic cancer, metastatic liver cancer and metastatic colorectal cancer. The therapeutic candidate is a tri-specific monoclonal antibody which acts by targeting hepatocyte growth factor receptor (HGFR, c-Met), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF). It is administered through intravenous route and is being developed based on HIO technology platform.
Tavotek Biotherapeutics overview
Tavotek Biotherapeutics (Tavotek) is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for oncology, autoimmune and inflammatory diseases. The company’s proprietary TavoMIP Platform uses small molecule and antibody drugs for Binding and targeting intracellular tumors; TavoSelect provides human antibody sequences that can be utilized in different formats using computational analysis and machine learning; and TavoPrecise, a fit-for-purpose monoclonal antibody, and multi-specific to identify unique epitopes. It has an operational presence in China. The company works in collaboration with Yisheng Biopharma Co Ltd, to discover, develop and commercialize biotherapeutics for cancer and infectious disease using its novel PIKA immunomodulating technology. Tavotek is headquartered in Lower Gwynedd, Pennsylvania, the US.
For a complete picture of TAVO-412’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
